Skip to main content
. Author manuscript; available in PMC: 2012 Aug 4.
Published in final edited form as: Int J Cardiol. 2010 May 15;150(3):264–269. doi: 10.1016/j.ijcard.2010.04.021

Table 2B.

Baseline variables of HFAdigHR<1 group vs. HFAdigHR-NS group.

HFAdigHR<1, n=6325 HFAdigHR-NS, n=1431 Odds ratio |Z| p value
Continuous/Ordinal variables (mean±SD)
Age (yrs) 64±11 62±12 6.1 <0.001
NYHA class 2.2±0.7 2.1±0.6 8 <0.001
SBP (mmHg) 123±18 141±17 30.4 <0.001
Heart rate (bpm) 79±12 77±14 5.9 <0.001
BMI 27±5 29±6 9.2 <0.001
Cardiothoracic ratio 0.5±0.07 0.5±0.07 2.3 0.02
EF (%) 30±12 40±13 26.6 <0.001
Creatinine (mg/dl) 1.3±0.4 1.3±0.4 4.7 <0.001
Categorical Variables (%)
Females 22 37 2.1 <0.001
Race (Caucasians) 87 81 0.6 <0.001
DM 28 31 1.3 0.009
Hypertension 42 71 3.3 <0.001
Ischemic etiology 70 66 0.8 0.02
Limitation of activity 76 74 0.07
Peripheral edema 23 12 0.4 <0.001
S3 28 6 0.2 <0.001
X-ray congestion 16 9 0.5 <0.001
ACE inhibitor use 94 92 0.8 0.03
Diuretic use 80 71 0.6 <0.001
Potassium sparing diuretic use 7 10 1.4 0.001
Digoxin use 50 49 0.64

p value of <0.001 was considered highly significant. Odds ratio and Z score are for variables in HFAdigHR-NS group in comparison with HFAdigHR<1 group. Odds ratio <0.5 or >2 and |Z|>10 was considered as a large effect size. Bold variables indicate a highly significant difference with a large effect size. BMI: body mass index; DM: diabetes mellitus; EF: ejection fraction; HFAdigHR<1: group with reduction in heart failure admissions with use of digoxin; HFAdigHR-NS: group with non-significant association of digoxin use with admissions due to heart failure; S3: third heart sound; SBP: systolic blood pressure.